Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Lilly Emerges as Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s $36.5 Billion Success
Eli Lilly and Company has officially concluded its fiscal year 2025 as the world’s leading pharmaceutical enterprise by revenue, a…
Read More
Eli Lilly Ascends to Pharma’s Top Revenue Spot Amidst Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced.
Eli Lilly and Company, a venerable titan in the pharmaceutical industry, has achieved an unprecedented milestone, claiming the top spot…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
Eli Lilly has ascended to the pinnacle of the pharmaceutical industry, claiming the top spot in the prestigious Pharma 50…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
Insilico Medicine, a pioneering company in artificial intelligence-driven drug discovery and development, has cemented a landmark global research and development…
Read More
Eli Lilly Expands In Vivo Gene Therapy Arsenal with $7 Billion Acquisition of Kelonia Therapeutics
Eli Lilly and Company has significantly bolstered its position in the rapidly evolving cell and gene therapy (CGT) landscape with…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, a pharmaceutical giant currently experiencing unprecedented growth driven by its blockbuster GLP-1 agonists, has announced an…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial.
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth
Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…
Read More
Eli Lilly is now pharma’s top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn’t celebrating
In a landmark announcement on April 1, the U.S. Food and Drug Administration (FDA) granted approval to Foundayo (orforglipron), Eli…
Read More
